English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
The global Cancer Pain Market was valued at USD 6.08 Billion in 2020 and is projected to grow at a compound annual growth rate (CAGR) of 4.3% during the forecast period. Factors such as the increasing prevalence of cancer worldwide, greater recognition of cancer pain as a significant clinical issue, rising use of opioids for managing cancer pain, and the identification of potential therapeutic targets to develop effective medications are expected to drive the growth of market revenue in the coming years. Additionally, the development of new treatment guidelines for cancer pain and advancements in Neuromodulation techniques, including the creation of non-invasive and cost-effective methods to address neuropathic cancer pain, are anticipated to further boost the market's revenue.
Cancer pain continues to be a significant global clinical challenge and is among the most dreaded aspects of the disease. A meta-analysis conducted previously revealed that 59% of cancer patients receiving anti-cancer treatment and 64% of patients with advanced and metastatic cancer experience severe cancer pain. The complexity of cancer pain as a biological phenomenon remains poorly understood and lacks accurate classification. Different mechanisms can contribute to cancer pain in each patient, which are likely to vary based on tumor-related and host-related factors and processes. While limited access to opioids remains a major obstacle in effectively managing cancer pain in many regions, pain remains prevalent in cancer patients and significantly affects clinical outcomes. With appropriate therapeutic approaches, excellent pain control can be achieved in over 90% of cancer patients. However, globally, cancer pain is widely undertreated due to factors such as low incomes, high cancer burden, and insufficient access to resources for pain relief in cancer patients.
Get a sample of the report @ https://www.reportsanddata.com/download-free-sample/4126
Competitive Landscape:
The global cancer pain market is slightly fragmented with presence of several players operating on a global and regional scale. Key players are engaged in product development and strategic alliances to cater to growing global demand and gain a robust footing in the market.
Major companies profiled in the market report include Sanofi SA, Teva Pharmaceuticals Industries Ltd., Johnson & Johnson, Daiichi Sankyo Company, BioDelivery Sciences International, Sorrento Therapeutics Inc., Pfizer Inc., Hisamitsu Pharmaceutical Co. Ltd., Orexo AB, and Insys Therapeutics Inc.
To know more about the report @ https://www.reportsanddata.com/report-detail/cancer-pain-market
Driving Factors of the Cancer Pain Market:
- Rising Prevalence of Cancer: The increasing incidence of cancer worldwide is a major driving factor for the cancer pain market. As the number of cancer patients grows, the demand for effective pain management solutions also increases.
- Growing Awareness of Cancer Pain: There is a greater recognition of cancer pain as a significant clinical problem. Healthcare professionals and patients are increasingly aware of the need for adequate pain control, leading to a higher demand for pain management therapies.
- Increased Consumption of Opioids: Opioids are commonly used to alleviate cancer pain. The growing consumption of opioids for pain management in cancer patients contributes to the expansion of the cancer pain market.
- Identification of Therapeutic Targets: Ongoing research has identified several potential therapeutic targets for developing effective pharmaceuticals to manage cancer pain. This knowledge drives the development of new pain management treatments and fuels market growth.
Restraints of the Cancer Pain Market:
- Inadequate Access to Opioids: Limited access to opioids, particularly in developing countries, remains a significant restraint in effectively managing cancer pain. Regulatory barriers, cultural factors, and concerns related to misuse and addiction hinder the availability of opioids for pain control.
- Undertreatment of Cancer Pain: Despite the availability of effective pain management options, cancer pain is often undertreated globally. Factors such as low income, high cancer burden, and insufficient resources for pain alleviation contribute to the undertreatment of cancer pain.
- Complex Nature of Cancer Pain: Cancer pain is a highly complex phenomenon, and its mechanisms are not yet fully understood or accurately classified. The diverse nature of pain mechanisms in different cancer patients poses challenges in developing targeted and personalized pain management approaches.
- Side Effects and Safety Concerns: Some pain management therapies for cancer pain may have side effects and safety concerns. Balancing pain control with minimizing adverse effects is a challenge that needs to be addressed in the development of new treatment options.
Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/4126
About Us:
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
Browse More Reports:
